PLAQ-MS

Other measures (8)

Inclusion Criteria Active MS-patients: * Informed consent form * At least one 0,5 cm diameter active gadolinium enhancing lesion detected lately * Diagnosed MS-disease according to McDonald criteria SPMS patients * Informed consent form * Diagnosed MS-disease according to McDonald criteria * SPMS disease Healthy controls: * Informed consent form * healthy * age and sex matched with MS-patients in RRMS and SPMS groups Exclusion Criteria MS-patients: * Patients suffering from another brain disease or other autoimmune disease in addition to multiple sclerosis * Steroid treatment 4 weeks prior to the scan * Significant pathology in the MRI scan other than MS-related lesions * Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan) * Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study * Age over 70 Healthy controls: * autoimmune disease, CNS disease or other serious disease * Steroid treatment 4 weeks prior to the scan or other regular medication * persons suffering from claustrophobia or panic disorder, or persons who have exhibited hypersensitivity of PET markers (practical obstacle to the scan) * Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study * Age over 70

To evaluate active MS plaque evolution with conventional MRI, QSM-post processing, TSPO-PET imaging and P2X7-PET imaging.